1 min read|68 words
A 25-year Danish register study found a modestly elevated risk of meningioma—a rare brain tumour—in women using progestogen-containing oral contraceptives. The Danish Medicines Agency has escalated the signal to the European PRAC for formal pharmacovigilance review. The absolute risk remains very low, and no immediate regulatory action has been taken. Stay informed as the EMA evaluates the risk-benefit profile.
Read the full article on GMJ Newsroom →
Was this article helpful?
